second nod, may10 2013–The US Food and Drug Administration has given the green light to Novartis’ Ilaris as a treatment for a serious form of childhood arthritis.

New Drug Approvals

my old post for first nod

Novartis’ Ilaris canakizumab has become the first biologic drug to be approved in the EU to treat the symptoms of gouty arthritis

Monoclonal antibody
Type Whole antibody
Source Human
Target IL-1β

http://cdn.medicosconsultants.com/images/7d271f3b-e4f9-4d80-8dcf-28d49123f80e/ilaris-02.jpg

Novartis’ Ilaris has become the first biologic drug to be approved in the EU to treat the symptoms of gouty arthritis in another gain for the interleukin-1 beta inhibitor.

march01,2013

First biologic drug approved for condition in Europe

The European Commission (EC) cleared llaris (canakizumab) for the treatment of adult patients who have suffered at least three gouty arthritis attacks in the previous 12 months, but who are unsuitable for treatment with non-steroidal anti-inflammatory drugs (NSAIDs) and colchicine or repeated courses of corticosteroids.

Gouty arthritis – commonly known as gout – is an “excruciating condition”, according to Novartis division head David Epstein, who noted that Ilaris offers new hope to patients who do not…

View original post 617 more words

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s